Get the Stockscreener App
3.415
0.44%
0.015
Relay Therapeutics Inc stock is traded at $3.415, with a volume of 375.53K.
It is up +0.44% in the last 24 hours and down -5.92% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$3.40
Open:
$3.35
24h Volume:
375.53K
Relative Volume:
0.20
Market Cap:
$588.78M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.2196
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+0.74%
1M Performance:
-5.92%
6M Performance:
-12.88%
1Y Performance:
-53.98%
1-Day Range:
$3.31
$3.42
1-Week Range:
$3.31
$3.65
52-Week Range:
$1.775
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.415 | 598.27M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.17 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.37 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.66 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
665.83 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
310.45 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics shares fall 2.45% intraday as Piper Sandler initiates coverage on Bicara Therapeutics. - AInvest
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts - Yahoo Finance
Published on: 2025-08-15 19:49:23 - beatles.ru
Relay Therapeutics Soars 13.57% on Earnings Beat - AInvest
Moving Average Crossover Confirms Uptrend in Relay Therapeutics Inc.July 2025 Intraday Action & Weekly Return Optimization Alerts - metal.it
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates - ADVFN Brasil
Relay Therapeutics’ SWOT analysis: AI-driven biotech’s stock faces pivotal phase - Investing.com India
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 89bio (ETNB), Relay Therapeutics (RLAY) and Ironwood Pharma (IRWD) - The Globe and Mail
Relay Therapeutics (RLAY) Receives Buy Rating from Leerink Partners with $12.00 Price Target - AInvest
Relay Therapeutics Reports Q2 2025 Financial Results and Progress - TipRanks
Raymond James Keeps 'Strong Buy' Rating on Relay Therapeutics but Lowers Price Target to $19 - AInvest
Will Relay Therapeutics Inc. continue its uptrendReal Time Growth Signal with Smart Setup - Newser
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $19 - 富途牛牛
Why Relay Therapeutics Inc. stock attracts strong analyst attentionGrowth Watchlist for Long Term Positioning - Newser
Screener Results Flag Relay Therapeutics Inc. as OversoldReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Analyst Downgrade - Defense World
Relay Therapeutics: Raymond James Maintains Strong Buy, PT Down to $19. - AInvest
RLAY.O Drops 11.7%: Uncovering the Forces Behind the Sudden Move - AInvest
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $4 to $17 - 富途牛牛
Wells Fargo reiterates Equal Weight rating on Relay Therapeutics stock By Investing.com - Investing.com Canada
Relay Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Relay Therapeutics reports Q2 EPS (41c), consensus (47c) - TipRanks
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Evaluating Relay Therapeutics' Momentum: Strategic Execution and Pipeline Progress in Q2 2025 - AInvest
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | RLAY Stock News - GuruFocus
Barclays Reiterates a Buy Rating on Relay Therapeutics (RLAY) - MSN
What’s the recovery path for long term holders of Relay Therapeutics Inc.Free Capital Preserving Trade Plan Templates - Newser
Relay Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowMomentum Screener with Buy and Sell Areas - Newser
Relay Therapeutics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Barclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT - MSN
Relay Therapeutics (RLAY) Expected to Announce Earnings on Thursday - Defense World
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - 富途牛牛
What makes Relay Therapeutics Inc. stock price move sharplyUnprecedented profits - Jammu Links News
10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey
How does Relay Therapeutics Inc. generate profit in a changing economyOutstanding stock performance - Jammu Links News
Should I hold or sell Relay Therapeutics Inc. stock in 2025Build a winning investment strategy today - Jammu Links News
Is Relay Therapeutics Inc. a good long term investmentDynamic profit opportunities - jammulinksnews.com
What are the latest earnings results for Relay Therapeutics Inc.Unlock exclusive stock market insights - Jammu Links News
Why is Relay Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
Critical Survey: SHINECO (NASDAQ:SISI) vs. Relay Therapeutics (NASDAQ:RLAY) - Defense World
What catalysts could drive Relay Therapeutics Inc. stock higher in 2025Discover stocks with superior performance - Jammu Links News
What drives Relay Therapeutics Inc. stock priceMaximize portfolio growth with professional advice - Jammu Links News
How does Relay Therapeutics Inc. compare to its industry peersGet alerts on high-potential market moves - Jammu Links News
Relay Therapeutics (RLAY): Is H2 2025 the Inflection Point for AI-Driven Drug Discovery? - AInvest
Relay Therapeutics: What's Next For H2 2025? - Seeking Alpha
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 - 富途牛牛
Relay Therapeutics Q2 2025 Financial Results and Corporate Highlights Announced for August 7, 2025 - AInvest
Relay Therapeutics’ Phase 3 Study: A New Hope for Advanced Breast Cancer Treatment - TipRanks
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Jul 28 '25 |
Sale |
3.74 |
1,359 |
5,083 |
393,722 |
| Catinazzo Thomas | Chief Financial Officer |
Jul 29 '25 |
Sale |
3.68 |
18,380 |
67,638 |
335,295 |
| Catinazzo Thomas | Chief Financial Officer |
Jul 28 '25 |
Sale |
3.74 |
1,701 |
6,362 |
353,675 |
| Bergstrom Donald A | President, R&D |
Jul 29 '25 |
Sale |
3.68 |
26,701 |
98,260 |
552,720 |
| Bergstrom Donald A | President, R&D |
Jul 28 '25 |
Sale |
3.74 |
4,069 |
15,218 |
579,421 |
| Adams Brian | Chief Legal Officer |
Jul 29 '25 |
Sale |
3.68 |
18,276 |
67,256 |
371,472 |
| Adams Brian | Chief Legal Officer |
Jul 28 '25 |
Sale |
3.74 |
1,637 |
6,122 |
389,748 |
| Patel Sanjiv | President and CEO |
Jul 09 '25 |
Sale |
3.57 |
61,379 |
219,123 |
765,288 |
| Rahmer Peter | See remarks |
Apr 30 '25 |
Sale |
3.00 |
10,739 |
32,217 |
390,081 |
| Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
1.08%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):